GB2594788B - Antagonist of PCSK9 - Google Patents

Antagonist of PCSK9 Download PDF

Info

Publication number
GB2594788B
GB2594788B GB2103594.4A GB202103594A GB2594788B GB 2594788 B GB2594788 B GB 2594788B GB 202103594 A GB202103594 A GB 202103594A GB 2594788 B GB2594788 B GB 2594788B
Authority
GB
United Kingdom
Prior art keywords
pcsk9
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2103594.4A
Other languages
English (en)
Other versions
GB2594788A (en
GB202103594D0 (en
Inventor
khan Michael
Mitchell Daniel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Argonaute RNA Ltd
Original Assignee
Argonaute RNA Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003756.0A external-priority patent/GB202003756D0/en
Priority claimed from GBGB2010276.0A external-priority patent/GB202010276D0/en
Priority claimed from GBGB2013998.6A external-priority patent/GB202013998D0/en
Priority claimed from GBGB2020553.0A external-priority patent/GB202020553D0/en
Application filed by Argonaute RNA Ltd filed Critical Argonaute RNA Ltd
Publication of GB202103594D0 publication Critical patent/GB202103594D0/en
Publication of GB2594788A publication Critical patent/GB2594788A/en
Application granted granted Critical
Publication of GB2594788B publication Critical patent/GB2594788B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21111—Aqualysin 1 (3.4.21.111)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21112—Site-1 protease (3.4.21.112), i.e. subtilisin kexin isozyme-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB2103594.4A 2020-03-16 2021-03-16 Antagonist of PCSK9 Active GB2594788B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2003756.0A GB202003756D0 (en) 2020-03-16 2020-03-16 Antagonist of PCSK9
GBGB2010276.0A GB202010276D0 (en) 2020-07-03 2020-07-03 PCSK9 antagonist
GBGB2013998.6A GB202013998D0 (en) 2020-09-07 2020-09-07 Antagonist of pcsk9
GBGB2020553.0A GB202020553D0 (en) 2020-12-23 2020-12-23 Antagonist of pcsk9

Publications (3)

Publication Number Publication Date
GB202103594D0 GB202103594D0 (en) 2021-04-28
GB2594788A GB2594788A (en) 2021-11-10
GB2594788B true GB2594788B (en) 2023-06-07

Family

ID=75111564

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2103594.4A Active GB2594788B (en) 2020-03-16 2021-03-16 Antagonist of PCSK9

Country Status (7)

Country Link
US (1) US20230183694A1 (enExample)
EP (1) EP4081642A1 (enExample)
JP (1) JP2023519140A (enExample)
CN (1) CN115066498A (enExample)
CA (1) CA3167849A1 (enExample)
GB (1) GB2594788B (enExample)
WO (1) WO2021185765A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US20250304966A1 (en) * 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
GB202020534D0 (en) * 2020-12-23 2021-02-03 Argonaute Rna Ltd Conjugate
EP4402263A2 (en) * 2021-09-14 2024-07-24 Argonaute Rna Limited Treatment of cardiovascular disease
GB2618915B (en) * 2022-05-18 2024-08-14 Argonaute Rna Ltd Treatment of cardiovascular disease
CN117106781B (zh) * 2023-10-16 2024-03-22 深圳市茵冠生物科技有限公司 修饰的核酸及其产品和应用
CN117210468B (zh) * 2023-11-06 2024-02-20 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
CN117384907B (zh) * 2023-12-11 2024-03-29 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用
CN121511305A (zh) * 2024-06-07 2026-02-10 迈威(上海)生物科技股份有限公司 一种抑制PCSK9基因表达的RNAi制剂及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166913A1 (en) * 2003-01-08 2006-07-27 Tsutomu Suzuki Process for producing sirna
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
EP2562257A1 (en) * 2010-04-19 2013-02-27 Riken Method for stabilizing functional nucleic acids
US20170000815A1 (en) * 2009-06-15 2017-01-05 Alnylam Pharmaceuticals, Inc. Lipid formulated dsrna targeting the pcsk9 gene
US20180216115A1 (en) * 2006-05-11 2018-08-02 Alnylam Pharmaceuticals, Inc. Compositions and Methods for Inhibiting Expression of the PCSK9 Gene

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN200950065Y (zh) 2006-05-24 2007-09-19 王锦峰 一种半自动夹板装置
CA2658183A1 (en) 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
BRPI0907008A2 (pt) 2008-01-31 2015-07-07 Alnylam Pharmaceuticals Inc Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
WO2009114475A2 (en) * 2008-03-09 2009-09-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
US9493774B2 (en) * 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
CA2816321A1 (en) * 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
AU2014300981B2 (en) * 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9
MX2018002158A (es) 2015-08-25 2018-07-06 Alnylam Pharmaceuticals Inc Mí‰TODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9).
KR20240067272A (ko) 2016-10-18 2024-05-16 노파르티스 아게 전구 단백질 전환효소 섭틸리신 켁신 9 (pcsk9) 단백질 감소를 통한 심혈관 사건의 예방 방법
CN109957565B (zh) * 2017-12-26 2023-04-07 广州市锐博生物科技有限公司 一种修饰的siRNA分子及其应用
WO2019126990A1 (zh) * 2017-12-26 2019-07-04 广州市锐博生物科技有限公司 一种抑制PCSK9基因表达的siRNA分子及其应用
CN117210468B (zh) * 2023-11-06 2024-02-20 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060166913A1 (en) * 2003-01-08 2006-07-27 Tsutomu Suzuki Process for producing sirna
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
US20180216115A1 (en) * 2006-05-11 2018-08-02 Alnylam Pharmaceuticals, Inc. Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
US20170000815A1 (en) * 2009-06-15 2017-01-05 Alnylam Pharmaceuticals, Inc. Lipid formulated dsrna targeting the pcsk9 gene
EP2562257A1 (en) * 2010-04-19 2013-02-27 Riken Method for stabilizing functional nucleic acids

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioconjugate Chemistry, Vol. 22, 2011, Abe et. al., "Synthesis, Structure, and Biological Activity of Dumbbell-Shaped Nanocircular RNAs for RNA Interference", pp. 2082-2092 *
Molecular therapy Nucleic acids, Vol. 2, e141, Allison et. al., "RNA interference by single- and double stranded siRNA with a DNA extension containing a 3' nuclease-resistant mini-hairpin structure" *

Also Published As

Publication number Publication date
US20230183694A1 (en) 2023-06-15
EP4081642A1 (en) 2022-11-02
GB2594788A (en) 2021-11-10
WO2021185765A1 (en) 2021-09-23
CA3167849A1 (en) 2021-09-23
CN115066498A (zh) 2022-09-16
JP2023519140A (ja) 2023-05-10
GB202103594D0 (en) 2021-04-28

Similar Documents

Publication Publication Date Title
GB202103594D0 (en) Antagonist of PCSK9
IL289534A (en) Parp1 inhibitors
IL279363A (en) PCSK9 antagonist compounds
PT3911648T (pt) 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização
IL277127A (en) Use of PCSK9 monitoring to reduce cardiovascular risk
ZA202212146B (en) Inhibitors of nek7 kinase
IL281939A (en) VAP-1 inhibitors
IL281815A (en) VAP-1 inhibitors
GB202103774D0 (en) Detectiion of Ransomware
PL4192814T3 (pl) Inhibitory transglutaminaz
GB202009064D0 (en) Compounds and methods of use
SI4192813T1 (sl) Zaviralci transglutaminaz
GB201810746D0 (en) Use of sclerostin antagonist
GB202113104D0 (en) Antagonist of pcsk9
GB202020553D0 (en) Antagonist of pcsk9
GB202013998D0 (en) Antagonist of pcsk9
GB202003756D0 (en) Antagonist of PCSK9
HUE055891T2 (hu) A gonadotropint felszabadító hormon (GNRH) receptor antagonista kristályos formája és annak elõállítási módja
IL309077A (en) Transglutaminase inhibitors
GB202207246D0 (en) PCSK9 antagonist
GB202010276D0 (en) PCSK9 antagonist
GB202215863D0 (en) Preparation of neosaxitoxin
GB202020554D0 (en) Antagonist of dgatii
GB202003758D0 (en) Antagonist of DGATII
GB202107612D0 (en) Inhibitors of metallo-beta-lactamases